Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G)

What is Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G)?

Complement 3 Glomerulopathy (C3G) is a rare disease caused by an overactive immune system, leading to deposit build-up in the kidneys and a decline in kidney function. There are two types of C3G due to the two types of damage that can be done to the kidneys: dense deposit disease (DDD and C3 glomerulonephritis (C3GN). The human immune system consists of many cell types in the blood circulation that detect, deliver, and attack any foreign bodies such as bacteria, viruses, small molecules, and other potentially harmful substances. The complement system is a group of proteins that are produced to activate and aid the immune system in fighting foreign invaders. These factors, also known as complement components, attach to foreign materials and deliver them to cells capable of destroying them. The most abundant complement factor is known as C3, and when it becomes activated, it begins to circulate in the blood at higher levels. The kidneys are responsible for filtering waste products out of the blood and exporting them via the urine, and high levels of C3 can become lodged into the glomeruli of the kidney and prevent this filtering function. This causes long-term damage to the kidney and is the root cause of C3G disease. 

Up until 2013, patients with C3G were diagnosed with membranoproliferative glomerulonephritis (MPGN) or mesangioproliferative glomerulonephritis. The reason for the renaming to C3G was due to differentiating diagnostic tests that could detect C3 deposits in the renal glomeruli of the kidney. These deposits differed slightly in appearance, but revealed essentially the same complement-mediated renal (kidney) disease, leading to both being redefined under the C3G umbrella term as DDD and C3GN. Based on the characteristics of their disease and the damage caused to their kidneys, MPGN 1 and 3 patients would now be diagnosed with C3GN, and MPGN 2 patients would now be diagnosed with DDD.

 

 

Synonyms

  • Complement 3 Glomerulonephritis
  • Dense Deposit Disease
  • Mesangioproliferative glomerulonephritis

Complement 3 Glomerulopathy (C3G) is a rare disease caused by an overactive immune system, leading to deposit build-up in the kidneys and a decline in kidney function. There are two types of C3G due to the two types of damage that can be done to the kidneys: dense deposit disease (DDD and C3 glomerulonephritis (C3GN). The human immune system consists of many cell types in the blood circulation that detect, deliver, and attack any foreign bodies such as bacteria, viruses, small molecules, and other potentially harmful substances. The complement system is a group of proteins that are produced to activate and aid the immune system in fighting foreign invaders. These factors, also known as complement components, attach to foreign materials and deliver them to cells capable of destroying them. The most abundant complement factor is known as C3, and when it becomes activated, it begins to circulate in the blood at higher levels. The kidneys are responsible for filtering waste products out of the blood and exporting them via the urine, and high levels of C3 can become lodged into the glomeruli of the kidney and prevent this filtering function. This causes long-term damage to the kidney and is the root cause of C3G disease. 

Up until 2013, patients with C3G were diagnosed with membranoproliferative glomerulonephritis (MPGN) or mesangioproliferative glomerulonephritis. The reason for the renaming to C3G was due to differentiating diagnostic tests that could detect C3 deposits in the renal glomeruli of the kidney. These deposits differed slightly in appearance, but revealed essentially the same complement-mediated renal (kidney) disease, leading to both being redefined under the C3G umbrella term as DDD and C3GN. Based on the characteristics of their disease and the damage caused to their kidneys, MPGN 1 and 3 patients would now be diagnosed with C3GN, and MPGN 2 patients would now be diagnosed with DDD.

 

Acknowledgement of Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G) has not been added yet.

C3G is a rare disease that affects people of all ages regardless of other factors. It has been estimated to occur in 2-3 people out of 1 million. In many cases, the average age of patients with the DDD type is lower than patients with C3GN. About 10-25% of C3G cases are linked to genetic mutations that affect the proteins that regulate the complement system.

 

Name Abbreviation
Complement 3 Glomerulonephritis C3GN
Dense Deposit Disease DDD
Mesangioproliferative glomerulonephritis MPGN

Complement 3 Glomerulopathy is caused by an abundance of C3 in the blood leading to blockage in the glomeruli of the kidney. In a normally functioning immune system, C3 proteins are activated by a protein called C3 convertase that cleaves the protein into its active form. The active C3 convertase is then deactivated by other proteins called complement factor H (fH) to stop cleaving C3 and effectively stop the immune response. However, individuals with C3G lack this system of regulation and C3 continues to circulate in the blood at increased levels. The body may lose these deactivating proteins in one of two ways. First, the deactivating fH proteins may not be produced in the body due to a genetic mutation that does not encode them. This is called genetic C3G. Second, the deactivating fH proteins may develop abnormally, sometimes as autoantibodies called C3 nephritic factors (C3Nefs). These C3Nefs stabilize the C3 convertase enzyme even in the presence of deactivation factors, causing acquired C3G. Cases of acquired C3G caused by C3Nefs have been more highly reported in children than adults. 

 

Individuals with the rare disease C3G experience many symptoms common to other kidney diseases. These include symptoms caused by the lack of filtration of toxins from the blood into the urine, such as:

  • Hematuria - blood in the urine

  • Proteinuria - protein in the urine, characterized by darker, cloudy urine

  • Hypoalbuminemia - low levels of protein in the blood, which can lead to leakage of water into the surrounding areas of the body and cause swelling of the hands, feet, ankles, etc. 

  • Reduced glomerular filtration rate (GFR) - reduced ability of the kidneys to filter toxins from the blood and release waste into the urine; can cause increased creatine levels

  • Fatigue

There is a membrane found in the eyes called the choriocapillaris-Bruch’s membrane that resembles a membrane found in the kidneys, the capillary-GBM membrane. Since this is where filtration occurs in the kidneys, it is also where deposits of C3 are found in cases of C3G. Some individuals with C3G may also experience build-up of C3 in this similar eye membrane, which can impact the retina and cause vision problems. 

 

Name Description
Hematuria Blood in the urine
Proteinuria Protein in the urine
Hyploalbuminemia Leakage leading to swelling

As with most rare diseases and disorders affecting the kidney, a specific molecule must be detected in kidney deposits to classify it as C3G. In this case, C3 must be detected in the glomerular capillaries using a technique called immunofluorescence. This will also enable the physician to distinguish the deposits’ characteristics to determine which type of C3G – DDD or C3GN – is present. Therefore, a kidney biopsy removing part of the kidney and examining it using fluorescent light microscopy is necessary to diagnose an individual with C3G.

Although a kidney biopsy is necessary to ultimately determine a diagnosis of C3G, other tests can be administered by physicians to investigate the likelihood of diagnosis. 

  1. Urine test - tests for high levels of protein or blood in the urine

  2. Blood test - tests for levels of complement proteins (C3) or waste products in the blood that are not filtering out due to damaged kidneys

  3. Glomerular filtration rate (GFR) - blood test that determines how well the kidneys filter waste out of the blood

  4. Kidney biopsy – a piece of the kidney is removed and examined for signs of high levels of C3 products; uses electron microscope that can magnify the glomeruli of kidneys 1000 times; determines the location of C3 in the glomeruli and whether the diagnosis is DDD or C3GN

There are currently no FDA-approved drugs designed specifically to treat C3G in patients. However, there are treatments for the symptoms of kidney problems to prevent or slow further kidney damage.

  1. Corticosteroids and immunosuppressants – Medications taken to calm the immune system and prevent it from overwhelming the glomeruli.

  2. Angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type-1 receptor blockers (ARBs) – Medications taken to control blood pressure and reduce protein loss from blood into urine; may also prevent white blood cells from entering the kidneys and delay progression of kidney damage; ex: lisinopril and ibesartan.

  3. Diet changes – a low sodium and low protein diet can prevent build-up of these wastes in the blood and therefore prevent them from overwhelming the kidneys’ filtration system.

  4. Mycophenolate mofetil immunosuppressant (MMF) – inhibits inosine monophosphate dehydrogenase enzyme, controls synthesis of guanine monophosphate and has been linked to better prognosis in individuals with C3GN (not DDD).

  5. Complement inhibitors – currently in development to counteract the complement system.

  6. Eculizumab – anti-complement drug that is an antibody (-mab suffix indicates an antibody therapeutic) that blocks C5 activity at the end of the complement protein pathway. This can decrease the amount of protein released into the urine and reduce the progression of kidney decline.

Patients with C3G will experience variances in the progression of the disease, and should consult with their doctor about a treatment plan to prevent or slow kidney damage. Some patients may respond well to treatments without the need for kidney transplants or dialysis, but still others may require these treatment options to prevent kidney failure. Consistent damage sustained to the glomeruli over a 10 year period can lead to kidney failure.

Antidote is conducting a new clinical trial and seeking individuals with C3G to participate: https://antidote.me/prescreener/s/complement_3_glomerulopathy-169?utm_source=RareShare&utm_medium=partner&utm_campaign=E169&utm_content=advocacy 

Clinical trials of complement protein inhibitors are being conducted by  ChemoCentryx and Achillion at the NIH Clinical Center in Bethesda, MD contact: prpl@cc.nih.gov

Visit https://kidneyhealthgateway.com/ for up-to-date clinical trials for any kidney diseases.

 

Logo

Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G) community discussions will be posted here.

There are no new discussions. Start one now!!

Community News Articles
Ric0pvrdqhzsoyxigzz5zu94brnct5evg6jcgxgfwycjtm gnyexyg4h1ytya8i4xwsnlk8yyekuelgxdyy6iern0z7frddutozfpvfzwgtvkuxuvsqimfpwtzs43v3txagxui18tfd6ka9ly9mp

Volunteers are needed for a kidney disease clinical trial.

Publication date: 2 Aug 2022

Community: Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G)

Complement 3 Glomerulonephritis (C3G) study is looking for volunteers.


Eo6qq2snz41kx2zsozgpth ia uao6k3db0f6jvtarwofnrmx8g3k8ecabflnupjksvw401yqtnlwskb1pccxbnl2 tfuojx7n3njbgmmazzxn9tpiywrujshs rxyp awrtzcqyinpmwhoozzlaikhvfoe5ie1sykedprsqoj1s 7glyn3eft4nwgttyj6hhpscc541

A Kidney Disease Trial is Enrolling Now

Publication date: 8 Dec 2022

Community: Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G)

Complement 3 Glomerulopathy study recruitment continues.


Community Resources
Title Description Date Link

Clinical Trials


Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit sanfordresearch.org/CoRDS to enroll.

Community Leaders

 

Expert Questions

Ask a question

Community User List


Start a Community


Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.

FAQ


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum

Logo

Membranoproliferative Glomerulonephritis (aka Complement 3 Glomerulopathy C3G) community discussions will be posted here.

There are no new discussions. Start one now!!


Communities

Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.

FIND YOUR COMMUNITY
Physicians

Our Resources

Our rare disease resources include e-books and podcasts

VIEW OUR EBOOKS

LISTEN TO OUR PODCASTS

VIEW OUR GUIDES

Leaders

Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.